Tiziana Life Sciences Ltd TLSA
At closeNov 3, 2026, 5:24 PM EST
After hours · Nov 3, 5:24 PM ET
- YTD
- -53.68%
- 1 year
- -62.90%
- Market cap
- 87.82M
- EPS (ttm)
- -0.21
- Shares out
- 103.82M
- Forward P/E
- -13.63
- YTD return
- -53.68%
- 1-year return
- -62.90%
- Volume
- 539.55K
- Avg volume
- 785.21K
- Open
- 0.6614
- Previous close
- 0.67
- Day's range
- 0.65 – 0.7263
- 52-week range
- 0.62 – 1.90
- Beta
- 0.18
- Earnings date
- Aug 9, 2024
2Y -0.2199 (-24.16%)
Key statistics
- Enterprise value
- 78.46M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 37.86
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -199.50K
- Total cash
- 1.13M
- Total debt
- 179.00K
- Return on equity
- -181.23%
- Short % of float
- 0.32%
- 50-day average
- 0.9492
- 200-day average
- 0.86445
Next earnings
Aug 9, 2024
Expected Aug 9, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 13, 2022 | ThinkEquity | init | — | Buy |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), an orally bioavailable small molecule broad spectrum inhibitor of various cyclin-dependent kinases and Src family; and TZLS-501, a fully human mAb targeting the IL-6 receptor for the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- Website
- tizianalifesciences.com
News
Tiziana's experimental MS treatment meets main goals in mid-stage study 
Tiziana Life Sciences Announces Topline Data In Phase 2a INFORM-MS Trial With Intranasal Foralumab In Patients With Na-SPMS; Trial Meets Dual Primary Endpoints 
Tiziana Management Team to Attend the 10th Joint ACTRIMS-ECTRIMS Meeting in Toronto 
Tiziana completes dosing in Phase 2 Alzheimer's trial of intranasal foralumab 
Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027 
Tiziana Doses Last Patient in Phase 2 Trial of Intranasal Foralumab for Mild Alzheimer's Disease 
12 Health Care Stocks Moving In Tuesday's Pre-Market Session 
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy 
Tiziana doses first three patients in ALS trial of nasal antibody foralumab - Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial
Your note
Sign in to keep a note on TLSA — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Sanctuary Advisors, LLC | 0.86% | 907,613 | 618.54K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.21% | 218,681 | 149.03K | Sep 29, 2024 |
| HSBC Holdings PLC | 0.11% | 115,365 | 78.62K | Sep 29, 2024 |
| Morgan Stanley | 0.10% | 109,747 | 74.79K | Sep 29, 2024 |
| Citadel Advisors Llc | 0.10% | 104,291 | 71.07K | Sep 29, 2024 |
| Kovitz Investment Group Partners, Llc | 0.08% | 79,365 | 54.09K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index ETF | 0.15% | 162,797 | 110.95K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 55,884 | 38.08K | Oct 30, 2024 |